Adaptive Biotechnologies (NASDAQ:ADPT) Insider Harlan Robins Sells 10,000 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 10,000 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.44, for a total transaction of $164,400.00. Following the sale, the insider owned 1,222,312 shares in the company, valued at approximately $20,094,809.28. This trade represents a 0.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Adaptive Biotechnologies Trading Down 4.6%

Adaptive Biotechnologies stock traded down $0.77 during midday trading on Thursday, reaching $15.96. 2,074,092 shares of the stock traded hands, compared to its average volume of 1,985,070. The firm has a fifty day moving average price of $16.48 and a two-hundred day moving average price of $14.25. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -29.56 and a beta of 2.18. Adaptive Biotechnologies Corporation has a fifty-two week low of $5.97 and a fifty-two week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The business had revenue of $93.97 million for the quarter, compared to analysts’ expectations of $58.76 million. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The company’s revenue was up 102.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.22) earnings per share. Analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Analyst Ratings Changes

ADPT has been the subject of a number of research analyst reports. Piper Sandler increased their target price on Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, October 15th. JPMorgan Chase & Co. increased their target price on shares of Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Guggenheim initiated coverage on Adaptive Biotechnologies in a report on Tuesday, September 30th. They set a “buy” rating and a $20.00 price objective for the company. Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, Morgan Stanley began coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target for the company. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $17.11.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Ameriprise Financial Inc. increased its stake in shares of Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after purchasing an additional 2,731,648 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in shares of Adaptive Biotechnologies by 544.0% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock worth $36,523,000 after acquiring an additional 2,062,282 shares during the last quarter. Summit Partners Public Asset Management LLC bought a new position in Adaptive Biotechnologies during the third quarter worth $14,934,000. First Trust Advisors LP raised its stake in Adaptive Biotechnologies by 4,802.2% during the 2nd quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock valued at $8,636,000 after purchasing an additional 726,184 shares during the last quarter. Finally, Peregrine Capital Management LLC bought a new stake in Adaptive Biotechnologies in the 2nd quarter valued at $8,187,000. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.